CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Provides Update on Advances in Brain Cancer Drugs and Operational Financials
Texas-based CNS Pharmaceuticals is a novel brain cancer drug developer that is building a series of global clinical trials for its lead drug candidate, BerubicinCNS began dosing patients in a global trial last September to evaluate Berubicin in treating glioblastoma multiforme (“GBM”), currently an incurable brain cancerCNS received FDA Fast Track designation for Berubicin in June 2021 and FDA Orphan Drug designation for Berubicin in…